JP2023106366A5 - - Google Patents

Download PDF

Info

Publication number
JP2023106366A5
JP2023106366A5 JP2023062212A JP2023062212A JP2023106366A5 JP 2023106366 A5 JP2023106366 A5 JP 2023106366A5 JP 2023062212 A JP2023062212 A JP 2023062212A JP 2023062212 A JP2023062212 A JP 2023062212A JP 2023106366 A5 JP2023106366 A5 JP 2023106366A5
Authority
JP
Japan
Prior art keywords
unsubstituted
substituted
formula
pharma
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2023062212A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023106366A (ja
Filing date
Publication date
Priority claimed from JP2020501505A external-priority patent/JP7260521B2/ja
Application filed filed Critical
Publication of JP2023106366A publication Critical patent/JP2023106366A/ja
Publication of JP2023106366A5 publication Critical patent/JP2023106366A5/ja
Priority to JP2024209477A priority Critical patent/JP2025060612A/ja
Withdrawn legal-status Critical Current

Links

JP2023062212A 2017-07-12 2023-04-06 タウタンパク質分解の化合物 Withdrawn JP2023106366A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024209477A JP2025060612A (ja) 2017-07-12 2024-12-02 タウタンパク質分解の化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762531773P 2017-07-12 2017-07-12
US62/531,773 2017-07-12
JP2020501505A JP7260521B2 (ja) 2017-07-12 2018-07-12 タウタンパク質分解の化合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020501505A Division JP7260521B2 (ja) 2017-07-12 2018-07-12 タウタンパク質分解の化合物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024209477A Division JP2025060612A (ja) 2017-07-12 2024-12-02 タウタンパク質分解の化合物

Publications (2)

Publication Number Publication Date
JP2023106366A JP2023106366A (ja) 2023-08-01
JP2023106366A5 true JP2023106366A5 (https=) 2024-04-16

Family

ID=65001509

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020501505A Active JP7260521B2 (ja) 2017-07-12 2018-07-12 タウタンパク質分解の化合物
JP2023062212A Withdrawn JP2023106366A (ja) 2017-07-12 2023-04-06 タウタンパク質分解の化合物
JP2024209477A Pending JP2025060612A (ja) 2017-07-12 2024-12-02 タウタンパク質分解の化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020501505A Active JP7260521B2 (ja) 2017-07-12 2018-07-12 タウタンパク質分解の化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024209477A Pending JP2025060612A (ja) 2017-07-12 2024-12-02 タウタンパク質分解の化合物

Country Status (7)

Country Link
US (2) US20210154184A1 (https=)
EP (2) EP3652329B1 (https=)
JP (3) JP7260521B2 (https=)
AU (1) AU2018300982B2 (https=)
CA (1) CA3069181A1 (https=)
ES (1) ES2965049T3 (https=)
WO (1) WO2019014429A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2767532T3 (en) 2012-12-21 2016-09-12 Nat Inst For Quantum And Radiological Science And Tech New connection for reproduction of tau protein heavy in the brain.
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
MX2019005007A (es) * 2016-11-01 2019-07-18 Arvinas Inc Protac dirigidos a la proteína tau y métodos asociados de uso.
SG11201907422RA (en) 2017-02-17 2019-09-27 Denali Therapeutics Inc Anti-tau antibodies and methods of use thereof
ES2965049T3 (es) * 2017-07-12 2024-04-10 Dana Farber Cancer Inst Inc Compuestos para la degradación de la proteína tau
PT3728207T (pt) 2017-12-21 2023-03-14 Ribon Therapeutics Inc Quinazolinonas como inibidores de parp14
CN111936498B (zh) 2018-03-26 2024-04-16 诺华股份有限公司 N-(3-(7H-吡咯并[2,3-d]嘧啶-4-基)苯基)苯甲酰胺衍生物
IL302595A (en) * 2018-04-13 2023-07-01 Arvinas Operations Inc Servalon ligands and bifunctional compounds containing them
FI3784663T3 (fi) 2018-04-23 2023-10-06 Celgene Corp Substituoituja 4-aminoisoindoliini-1,3-dioniyhdisteitä ja niiden käyttö lymfooman hoitamiseksi
TW201946624A (zh) 2018-05-09 2019-12-16 新旭生技股份有限公司 雜芳基化合物及其用途
WO2020027225A1 (ja) 2018-07-31 2020-02-06 ファイメクス株式会社 複素環化合物
JP7297053B2 (ja) 2018-08-20 2023-06-23 アルビナス・オペレーションズ・インコーポレイテッド 神経変性疾患を治療するためのe3ユビキチンリガーゼ結合活性を有するキメラ(protac)化合物を標的とし、アルファ-シヌクレインタンパク質を標的とするタンパク質分解
US11389438B2 (en) * 2019-02-25 2022-07-19 Chdi Foundation, Inc. Compounds for targeting mutant huntingtin protein and uses thereof
WO2020210630A1 (en) 2019-04-12 2020-10-15 C4 Therapeutics, Inc. Tricyclic degraders of ikaros and aiolos
CA3142002A1 (en) * 2019-06-19 2020-12-24 Ribon Therapeutics, Inc. Targeted protein degradation of parp14 for use in therapy
EP3999182A1 (en) * 2019-07-17 2022-05-25 Arvinas Operations, Inc. Tau-protein targeting compounds and associated methods of use
CN114521196A (zh) * 2019-09-16 2022-05-20 诺华股份有限公司 双官能团降解剂及其使用方法
CN114728071B (zh) * 2019-11-13 2024-12-06 新旭生技股份有限公司 用于降解tau蛋白聚集体的化合物及其用途
CN110878095B (zh) * 2019-12-02 2023-01-24 中山大学 一种姜黄素双功能分子及其制备方法和应用
EP4121046A4 (en) * 2020-03-18 2024-04-24 Dana-Farber Cancer Institute, Inc. Targeted degraders of aberrant tau based on the pet tracer pbb3
EP4138921A1 (en) * 2020-04-23 2023-03-01 University Of Iowa Research Foundation Gper proteolytic targeting chimeras
CA3183431A1 (en) * 2020-05-15 2021-11-18 Vib Vzw Means and methods for the treatment of pathological aggregation
KR20230018431A (ko) * 2020-05-28 2023-02-07 브리스톨-마이어스 스큅 컴퍼니 갈렉틴-3 억제제
AU2021293907A1 (en) * 2020-06-17 2023-01-19 Dana-Farber Cancer Institute, Inc. Targeted aberrant alpha-synuclein species and induced ubiquitination and proteosomal clearance via co-recruitment of an E3-ligase system
WO2022201063A1 (en) * 2021-03-23 2022-09-29 Covabind Joint Research Private Limited Nanoparticle composition for targeted protein degradation
EP4337259A1 (en) 2021-05-14 2024-03-20 Aprinoia Therapeutics Limited Compounds for degrading alpha-synuclein aggregates and uses thereof
EP4351574B1 (en) 2021-06-07 2026-03-04 The General Hospital Corporation Inhibitors of ttbk1
CN115504963A (zh) * 2021-06-22 2022-12-23 苏州开拓药业股份有限公司 一种c-Myc蛋白降解剂
EP4147723A1 (en) 2021-09-09 2023-03-15 Booster Therapeutics GmbH Bifunctional molecules as proteasome stimulators for improved targeted protein degradation, and their uses as targeted boosting degraders (tarbods)
EP4398941A1 (en) * 2021-09-09 2024-07-17 Booster Therapeutics GmbH Bifunctional molecules as proteasome stimulators for improved targeted protein degradation, and their uses as targeted boosting degraders (tarbods)
WO2024081690A2 (en) * 2022-10-11 2024-04-18 The General Hospital Corporation Engineered bifunctional receptors and uses thereof
WO2024182633A2 (en) * 2023-03-01 2024-09-06 The Regents Of The University Of California Targeted dephosphorylation of tau
CN116344058B (zh) * 2023-05-29 2023-08-18 之江实验室 一种基于图信号的阿尔兹海默风险标注方法及装置
WO2025117551A1 (en) * 2023-11-27 2025-06-05 Amydis, Inc. Amino acid derivatives for detecting neurological disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8932557B2 (en) * 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
US9378662B2 (en) 2011-08-04 2016-06-28 Ats Holdings Llc Simplified spine testing device
TW201605852A (zh) * 2013-09-26 2016-02-16 美國禮來大藥廠 新穎化合物及其製備tau造影劑及tau造影調配物之用途
CA2920068A1 (en) * 2013-09-26 2015-04-02 F. Hoffmann-La Roche Ag Imidazo[1,2-a]pyridin-7-amines as imaging tools
EP3061748A4 (en) 2013-10-22 2017-04-05 Clino Ltd. Tau imaging probe
RU2738833C9 (ru) * 2014-04-14 2022-02-28 Арвинас, Оперэйшнз, Инк. Имидные модуляторы протеолиза и способы их применения
WO2016105518A1 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
CA2988414C (en) 2015-06-04 2023-09-26 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
BR112017028269A2 (pt) * 2015-07-13 2018-09-04 Arvinas Inc composto, composição farmacêutica, uso de uma quantidade efetiva de um composto, estado ou condição de doença, e, método para identificar um composto.
WO2017024318A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
US10772962B2 (en) * 2015-08-19 2020-09-15 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
MX2019005007A (es) * 2016-11-01 2019-07-18 Arvinas Inc Protac dirigidos a la proteína tau y métodos asociados de uso.
CN106543185B (zh) * 2016-11-10 2017-12-15 吉林大学 一种靶向泛素化降解plk1和brd4蛋白的化合物及其应用
ES2965049T3 (es) * 2017-07-12 2024-04-10 Dana Farber Cancer Inst Inc Compuestos para la degradación de la proteína tau

Similar Documents

Publication Publication Date Title
JP2023106366A5 (https=)
JP2020527559A5 (https=)
JP2012507522A5 (https=)
RU2009104764A (ru) Производные пурина, как антангонисты a2a
US20240308984A1 (en) Jak Inhibitor With High Oral Bioavailability
JP2008517983A5 (https=)
IL280075B1 (en) A conjugated tricyclic compound as a dual PDE3/PDE4 inhibitor
AU2019374812A1 (en) Pyridazinone compounds and uses thereof
EP2963033B1 (en) Benzimidazole-4-carboxamide derivates, their preparation methods, pharmaceutical compositions and their uses
WO2014164667A1 (en) Dengue and west nile virus protease inhibitors
JP2005533013A5 (https=)
JP2023538524A5 (https=)
WO2010135427A2 (en) Trioxane monomers and dimers
CN102526087B (zh) 核苷类化合物在制备治疗肠病毒71(ev71)感染疾病药物的应用
JP2007505044A5 (https=)
JP2023103364A (ja) 化合物、その薬学的に許容される塩又は立体異性体、及びその使用
JP2008524218A5 (https=)
RU2012109220A (ru) Новые соединения и их терапевтическое использование для ингибирования протеинкиназы
JP2023502605A5 (https=)
JP2024540303A5 (https=)
JP2025500176A (ja) カルボン酸バイオアイソスタを含むdhodh阻害剤
JP4393376B2 (ja) フェニルシクロヘキシルプロパノールアミン誘導体、その製造法、およびその治療的適用
EP2927219B1 (en) 2-aryl selenazole compound and pharmaceutical composition thereof
JP2023552274A (ja) 抗ウイルス化合物としての重水素化アミノチアゾール化合物
RU2011108485A (ru) Новые (поли)аминоалкиламиноалкиламидные, алкилмочевинные или алкилсульфонамидные производные эпиподофиллотоксина, способ их получения и их применение в терапии в качестве противораковых средств